Latest Ratios: P/E Ratio 0.0x · EV/EBITDA N/A · ROE -55.9%. (2020–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $21M | $16M | — | — | — | — |
| Enterprise Value | $803M | $798M | — | — | — | — |
| P/E Ratio → | 0.00 | — | — | — | — | — |
| P/S Ratio | 1.14 | 0.87 | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 43.74 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 47.4% | 47.4% | 72.2% | 91.2% | 96.4% | 98.8% |
| Operating Margin | -6982.8% | -6982.8% | -7266.3% | -1415.4% | -49.0% | -24.0% |
| Net Profit Margin | -1975.4% | -1975.4% | -731.3% | -31.7% | -226.3% | -174.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -55.9% | -55.9% | -3.1% | -0.7% | — | — |
| ROA | -14.2% | -14.2% | -1.7% | -0.4% | -54.3% | -135.9% |
| ROIC | -69.7% | -69.7% | -18.3% | -19.4% | — | — |
| ROCE | -67.7% | -67.7% | -17.5% | -19.8% | -55.9% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.48 | 0.15 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 0.47 | 0.15 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | 130.99 | — |
| Interest Coverage | -2.71 | -2.71 | -1.89 | -2.32 | -0.22 | -0.16 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.01 | 0.01 | 0.47 | 0.44 | 0.35 | 0.40 |
| Quick Ratio | 0.01 | 0.01 | 0.47 | 0.44 | 0.35 | 0.40 |
| Cash Ratio | 0.01 | 0.01 | 0.25 | 0.03 | 0.03 | 0.28 |
| Asset Turnover | — | 0.01 | 0.00 | 0.01 | 0.14 | 0.78 |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | 29.98 | 66.56 | 134.34 | 101.57 | 128.03 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $1M | $356591 | $98920 | $121175 | $9M |
Liquidity and insolvency risk
Based on reported figures, MSPR trades at a price-to-sales ratio of 0.76, which appears to reflect significant market skepticism regarding the company's ability to convert its legal-centric asset portfolio into sustainable, recurring revenue streams compared to traditional healthcare information services peers.
The absence of meaningful P/E or EV/EBITDA multiples suggests that the market is currently pricing the firm as a distressed asset rather than a growth-oriented technology provider. Investors should monitor whether this valuation discount is a permanent reflection of the company's litigation-heavy business model or a temporary mispricing of its underlying claim recovery potential.
As indicated by recent financial statements, the company's ROIC has trended deeply into negative territory, reaching -110.2% in 2025Q3, which highlights a fundamental inability to generate positive returns on the capital deployed into its legal claim acquisition and data infrastructure strategy.
This consistent decay in returns suggests that the cost of acquiring and litigating claims significantly outweighs the cash inflows generated from settlements. The negative ROIC trend warrants further investigation into whether the company's capital allocation strategy is inherently value-destructive or merely suffering from a prolonged gestation period for its legal assets.
According to quarterly data, the company's asset turnover remains effectively at zero, while DSO figures have spiked as high as 730 days, illustrating a severe disconnect between operational activity and the actual realization of cash from its healthcare recovery services.
The extreme length of the cash conversion cycle suggests that the company is struggling to monetize its claims in a timely manner, placing immense pressure on its limited liquidity. This inefficiency appears structural, as the reliance on legal outcomes inherently prevents the rapid turnover of assets seen in more traditional service-based healthcare models.
As reported in recent filings, the current ratio has plummeted to 0.01, indicating that the company possesses virtually no liquid assets to cover its immediate obligations, a position that leaves the firm highly vulnerable to any disruption in its legal settlement pipeline.
The near-zero quick ratio suggests that the company is operating with almost no margin for error, making it entirely dependent on external financing or lumpy, unpredictable legal settlements to maintain operations. This liquidity profile appears unsustainable and warrants close monitoring for potential insolvency risks if the current cash burn continues unabated.
The most commonly misapplied metric for MSPR is the price-to-sales ratio, which erroneously treats the company as a high-margin software firm rather than a high-stakes litigation funder, thereby obscuring the massive legal and operational costs inherent in its business model.
Investors should instead focus on the 'Total Billed Amount' and 'Settlement Velocity' as more accurate indicators of the company's true earning power. Relying on traditional SaaS multiples ignores the binary risk and capital intensity of the firm's legal-centric revenue recognition, which is fundamentally different from recurring subscription-based software models.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MSPR stock.
MSP Recovery, Inc.'s current P/E ratio is 0.0x.
MSP Recovery, Inc.'s return on equity (ROE) is -55.9%. The historical average is -19.9%.
Based on historical data, MSP Recovery, Inc. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
MSP Recovery, Inc. has 47.4% gross margin and -6982.8% operating margin.